DK0951908T3 - Behandling af impotens på grund af rygmarvsskade - Google Patents

Behandling af impotens på grund af rygmarvsskade

Info

Publication number
DK0951908T3
DK0951908T3 DK99301085T DK99301085T DK0951908T3 DK 0951908 T3 DK0951908 T3 DK 0951908T3 DK 99301085 T DK99301085 T DK 99301085T DK 99301085 T DK99301085 T DK 99301085T DK 0951908 T3 DK0951908 T3 DK 0951908T3
Authority
DK
Denmark
Prior art keywords
spinal cord
cord injury
treatment
impotence due
male
Prior art date
Application number
DK99301085T
Other languages
Danish (da)
English (en)
Inventor
Murray Craig Maytom
Ian Howard Osterloh
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Application granted granted Critical
Publication of DK0951908T3 publication Critical patent/DK0951908T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
DK99301085T 1998-02-23 1999-02-15 Behandling af impotens på grund af rygmarvsskade DK0951908T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
DK0951908T3 true DK0951908T3 (da) 2004-12-27

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99301085T DK0951908T3 (da) 1998-02-23 1999-02-15 Behandling af impotens på grund af rygmarvsskade

Country Status (17)

Country Link
US (1) US20060040935A1 (zh)
EP (1) EP0951908B1 (zh)
JP (1) JPH11315025A (zh)
KR (1) KR19990072798A (zh)
AT (1) ATE279194T1 (zh)
AU (1) AU755402B2 (zh)
CA (1) CA2262268C (zh)
DE (1) DE69921008T2 (zh)
DK (1) DK0951908T3 (zh)
ES (1) ES2226281T3 (zh)
HU (1) HUP9900438A3 (zh)
IL (1) IL128532A0 (zh)
MY (1) MY133446A (zh)
NZ (1) NZ334333A (zh)
PT (1) PT951908E (zh)
TW (1) TW542719B (zh)
ZA (1) ZA991393B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
JP2002543128A (ja) 1999-04-30 2002-12-17 リリー アイコス リミテッド ライアビリティ カンパニー 雌性覚醒障害の処置
JP2003519150A (ja) 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト 新規なイミダゾ［１，３，５］トリアジノン類及びその使用
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
MXPA06013133A (es) 2004-05-11 2007-05-23 Emotional Brain Bv Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
ES2226281T3 (es) 2005-03-16
PT951908E (pt) 2005-01-31
AU755402B2 (en) 2002-12-12
HU9900438D0 (en) 1999-04-28
MY133446A (en) 2007-11-30
EP0951908B1 (en) 2004-10-13
HUP9900438A2 (hu) 2000-03-28
DE69921008T2 (de) 2006-02-02
CA2262268A1 (en) 1999-08-23
JPH11315025A (ja) 1999-11-16
DE69921008D1 (de) 2004-11-18
ZA991393B (en) 2000-08-22
IL128532A0 (en) 2000-01-31
US20060040935A1 (en) 2006-02-23
KR19990072798A (ko) 1999-09-27
TW542719B (en) 2003-07-21
EP0951908A2 (en) 1999-10-27
ATE279194T1 (de) 2004-10-15
EP0951908A3 (en) 2000-08-16
AU1839099A (en) 1999-09-09
NZ334333A (en) 2000-11-24
HUP9900438A3 (en) 2002-01-28
CA2262268C (en) 2003-07-29

Similar Documents

Publication Publication Date Title
DK0951908T3 (da) Behandling af impotens på grund af rygmarvsskade
PA8476301A1 (es) Formulaciones intranasales para tratar trastornos sexuales
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
ITMI20020990A0 (it) Formulazioni utili nel trattamento dell'impotenza maschile e femminile
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
ID24184A (id) Obat untuk perawatan disfungsi ereksi
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
NO20062883L (no) Fosfodiesterase-V-inhibitorpreparater
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
PL1818052T3 (pl) Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
ECSP993027A (es) Formulaciones intranasales para trastornos sexuales
ES2092685T3 (es) Uso de atipamezol para el tratamiento de impotencia sexual masculina.
GB9928178D0 (en) Agent for the treatment of male and female sexual dysfunction
CA2203379A1 (en) Cgmp-pde inhibitors for the treatment of erectile dysfunction
GEP20043347B (en) Use of Pyrazolopyrimidinones for Treatment of Impotence
GB0108730D0 (en) Treatment of male sexual dysfunction
GB0106167D0 (en) Treatment of male sexual dysfunction
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina